Our antibody development platform addresses the urgent need for monoclonal antibodies with unprecedented specificity to native or denatured proteins.REQUEST INFO
CDI Labs' monoclonal antibody development, production and purification, along with HuProt™ microarray specificity validation, is (approximately) an 8-week process. It is a milestone-driven, 4-phase process with client reporting and assessment exchanged at each step. Invoicing begins at the initiation of Phase 1 and at the completion of each phase thereafter. Milestones represent potential endpoints that depend on your project requirements or if the results-to-date fail to meet your expectations.
Our antibody development platform addresses the urgent need for monoclonal antibodies with unprecedented specificity to native or denatured proteins.
Antigen design, immunization strategy and screening methodology are critical to achieving high-value results. CDI Labs offers a fully-customized development process to meet the requirements and provide a quote based on deliverables.
5-mouse immunization regimen using as little as 200 μg client-supplied protein of >80% purity or carrier-conjugated peptide. We also offer assistance in antigen design and synthesis.
2 top-responding animals are chosen, and immune cells are harvested for fusion with myeloma cells yielding multiple hybridomas. Supernatants from IgG-secreting clones are screened by ELISA.
A minimum of 5 to a maximum of 30 high-quality clones are chosen and sub-cloned. Each is expanded into 24-well plates and subsequently into T-25 flasks. Supernatants are shipped for further client evaluation.
Each clone is vialed, labeled and frozen. Samples of each are reserved for mycoplasma testing. Per client instructions, 3 select clones are placed into antibody production. The resulting antibodies are purified and evaluated with HuProt Human Proteome Microarray.
Detailed specificity data and additional QA documentation are prepared and shipped along with the purified antibodies and all frozen clones.